Analysts Offer Insights on Healthcare Companies: CymaBay Therapeutics (NASDAQ: CBAY) and Arrowhead Pharmaceuticals (NASDAQ: ARWR)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on CymaBay Therapeutics (CBAYResearch Report) and Arrowhead Pharmaceuticals (ARWRResearch Report).

CymaBay Therapeutics (CBAY)

In a report issued on May 7, Patrick Dolezal from LifeSci Capital maintained a Buy rating on CymaBay Therapeutics, with a price target of $12.00. The company’s shares closed last Thursday at $4.34.

According to TipRanks.com, Dolezal is a 3-star analyst with an average return of 12.4% and a 39.1% success rate. Dolezal covers the Healthcare sector, focusing on stocks such as Adverum Biotechnologies, Rocket Pharmaceuticals, and Tarsus Pharmaceuticals.

Currently, the analyst consensus on CymaBay Therapeutics is a Strong Buy with an average price target of $11.78, which is a 182.8% upside from current levels. In a report issued on May 14, H.C. Wainwright also maintained a Buy rating on the stock with a $13.00 price target.

See today’s analyst top recommended stocks >>

Arrowhead Pharmaceuticals (ARWR)

Robert W. Baird analyst Joel Beatty maintained a Hold rating on Arrowhead Pharmaceuticals on July 2 and set a price target of $79.00. The company’s shares closed last Thursday at $65.32.

According to TipRanks.com, Beatty is a 4-star analyst with an average return of 9.2% and a 49.7% success rate. Beatty covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, BioMarin Pharmaceutical, and Syndax Pharmaceuticals.

Arrowhead Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $91.17, implying a 46.2% upside from current levels. In a report issued on June 23, Leerink Partners also maintained a Hold rating on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.